Euphrasia officinalis 30c homeopathic tablets
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Homeopathic euphrasia officinales on the MHRA register
Euphrasia officinalis 30c homeopathic tablets
Euphrasia officinalis 30c homeopathic tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 23 studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · 1998–2026
Showing all 23 studies, sorted by most relevant.
L. Sharma
ShodhKosh: Journal of Visual and Performing Arts, 2024
Rheumatoid arthritis (RA) is a chronic, multisystem autoimmune disorder characterized by inflammation of the synovial joints, leading to pain, swelling, stiffness, and progressive joint damage. Conventional treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologics, are effective but often associated with adverse effects such as gastrointestinal bleeding, hepatotoxicity, and increased infection risk. In this context, homeopathy has emerged as a complementary and alternative medicine (CAM) approach for managing RA. This review explores the mechanisms of action of homeopathic drugs in RA, focusing on immunomodulation, anti-inflammatory effects, and cytokine regulation. Preclinical studies demonstrate that remedies like Arnica montana, Ruta graveolens ,and Guaiacum officinale exhibit significant anti-inflammatory and antioxidant properties by modulating immune cells, reducing pro-inflammatory cytokines, and mitigating oxidative stress. Clinical evidence, though limited, suggests potential benefits of homeopathic drugs in improving symptoms, reducing inflammation, and enhancing quality of life. While these findings highlight the therapeutic potential of homeopathy in RA, further large-scale, randomized controlled trials are needed to validate its efficacy and establish its role as a complementary treatment.
Abstract licence: CC BY
P. Aphale, H. Shekhar, S. Dokania
Alternative therapies in health and medicine, 2025
S. Dokania, P. Aphale, Neeta Mishra
International Journal of High Dilution Research - ISSN 1982-6206, 2025
Introduction: Dry eye syndrome (DES) is denoted as a habitual condition reducing either the production of tears or quick evaporation of the tears. This imbalance predominantly affects the tear film, essential for the maintenance of general well being of the eye and comfort. Symptoms often include dryness, itchiness, burning, a gritty sensation, and blurred vision. About 5%-35% of the population is affected with DES. Tear Breakup Time, also referred to as TBUT, is a measurement used to assess the quality of the film on the ocular surface. The tear ocular film is a thin layer of fluid that coats the eye, providing lubrication and protection. Aim and Objectives: To assess the efficacy of homoeopathic formulation of Euphrasia Officinalis as Eye Drops in management of DES. Methodology: A prospective, interventional, experimental study was conducted on 32 patients fitting into the inclusion/exclusion criteria for duration of 30 days. Tear BreakUp Test (TBUT) as laid down in the protocol was conducted at baseline, 15th day and 30th day. Visual acuity was measured and noted. Homeopathic Case Report Assessment Scale (HCRAS) data was interpreted on day 30 to assess amelioration of presenting complaints. Results: There was marked increase in TBUT at the 15th day (n=64 eyes) compared to baseline which was particularly noteworthy (p30) in HCRAS findings recorded at 30th day. Conclusion: Homoeopathic formulation of Euphrasia Officinalis as eye drops was considered to be significant in improving TBUT levels, enhancing tear production and managing DES.
Abstract licence: CC BY-NC-SA
Ana Catarina Viana Valle
World Journal of Medicine and Health Care, 2024
A. Verkhozina, Vladimir A. Agafonov, A. Ageeva, et al.
Botanica Pacifica, 2024
With this paper we continue an annual series, the main purpose of which is to make significant floristic findings from Russia and neighboring countries more visible in Russia and abroad. In total, this paper presents new records for 60 vascular plant species from 5 Eurasian countries, obtained during field explorations, as well as during taxonomic revisions of herbarium materials. For the first time, Clematis tangutica, Cynoglossum asperrimum, and Potentilla hubsugulica are recorded for Russia, Azolla filiculoides for Uzbekistan and Central Asia, Hackelia popovii for China and Kyrgyzstan, Chamaerhodos erecta for Kyrgyzstan, Astragalus tatjanae, Centaurea tadshicorum, Cynosurus echinatus, Epipactis persica, Eremurus × decoloratus, Euphrasia drosophylla, Fritillaria rugillosa, Paspalum distichum, Plagiobasis centauroides for Uzbekistan, Poa turfosa for the Yamal-Nenets Autonomous Area, as well as for the Siberian arctic-hyparctic floristic province and the entire Arctic and Hyparctic Asia, Carduus × semiperegrinus, Reynoutria × bohemica for Siberia, Artemisia obtusiloba subsp. martjanovii for Baikal Siberia, Callitriche cophocarpa for the Republic of Altai, Krasnoyarsk Territory, Kemerovo and Tomsk regions, Prunella vulgaris for the Magadan Region and Chukotka Autonomous Area, Cynoglossum officinale for the Republic of Buryatia, Carex buxbaumii, Epipactis microphylla for the Republic of Dagestan, Tripleurospermum elongatum for the Kabardino-Balkaria Republic, Anthyllis vulneraria, Malva moschata, Menispermum dauricum, Persicaria orientalis, Petrosedum rupestre, Rubus occidentalis, R. procerus, Vitis amurensis for the Republic of Mordovia, Oxytropis caespitosa for the Tyva Republic, Myosotis sparsiflora, Pedicularis spicata for the Magadan Region and northern part of the Russian Far East, Astragalus arkalycensis, Bolboschoenus laticarpus, Limonium suffruticosum for the Omsk Region, Arabidopsis arenosa for the Tomsk Region, Asparagus pallasii, Astragalus cicer, Sisymbrium altissimum for the Tyumen Region, Thymus dimorphus for the Volgograd Region, Botrychium boreale for the Vologda Region, Thymus kondratjukii for the Voronezh Region, Rudbeckia triloba, Stachys byzantina for the Rostov Region, Geranium turczaninovii for the Almaty Region of Kazakhstan, Potentilla thuringiaca for the Karaganda Region of Kazakhstan and the Kazakh uplands (Kazakhskiy Melkosopochnik), Egeria densa for the Hunan Province and Elodea nuttallii for the Jiang su Province of China.
Abstract licence: CC BY-NC
Dr. Roni V Dudhwala, Aarati N Gohil
International Journal of Medical Ophthalmology, 2023
A. Valle, Aloíso Carvalho, Samir Rahme, et al.
Medical Research Archives, 2023
Monesh Likhitkar
Journal of Advances and Scholarly Researches in Allied Education, 2023
The use of herbal remedies as treatment agents for a variety of illnesses has achieved widespread acceptance. One of the biggest challenges that scientists have is creating reliable analytical techniques to profile phytochemical content. This includes quantitative assessments of marker/bioactive chemicals and other important components. The development of a quality assurance program, uniform chemical profiles, or consistent biological activities in herbal medicine manufacture and manufacturing all need standardization. In order to achieve worldwide harmonization, it is crucial to have WHO-specific standards for evaluating the quality, safety, and effectiveness of herbal medicines. Traditional Ayurvedic, Siddha, and Homeopathic medicine have long made use of medicinal plants like Curcuma longa, Aloe barbadenis, Coriandrum sativam, Azadirachta indica, and zingiber officinale. The aforementioned five therapeutic plants also find usage in the cosmetic and pharmaceutical industries. The field studying anti-inflammatory action may benefit from this research report. Using the extract of the specified herbal plant product, these polyherbal tablets were manufactured. Reduce inflammation and inflammatory symptoms with this polyherbal pill.
Abstract licence: CC BY-SA
M. C. Pereira, Thainá Beatriz Soares, J. Stroparo, et al.
DNA and cell biology, 2026
E. Porchezhian, S. Ansari, N.K.K Shreedharan
Fitoterapia, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.